InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,572.85
(
0.10%
)
US TECH 100
19,965.20
(
0.36%
)
Dow Jones
39,344.79
(
-0.08%
)
Brent Oil
85.14
(
-0.33%
)
Bitcoin
57,472.36
(
1.35%
)
Post# of 252526
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 119993
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 93667

Thursday, 07/24/2014 5:53:59 PM

Thursday, July 24, 2014 5:53:59 PM

Post# of 252526
FDA accepts for review NVS’ 351(k) Neupogen-FoB submission:

http://www.novartis.com/newsroom/media-releases/en/2014/1835571.shtml

This is the first 351(k) submission ever accepted by the FDA.

351(k) is the designation for the FoB-approval pathway established in 2010 as part of the ObamaCare legislation (#msg-48581353).

NVS’ Neupogen FoB is already marketed in more than 40 countries under the brand name, Zarzio.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up